These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22120252)

  • 1. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.
    Soppi V; Karamanakos PN; Koivisto T; Kurki MI; Vanninen R; Jaaskelainen JE; Rinne J
    World Neurosurg; 2012 Jul; 78(1-2):101-9. PubMed ID: 22120252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
    Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
    Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.
    Kronvall E; Undrén P; Romner B; Säveland H; Cronqvist M; Nilsson OG
    J Neurosurg; 2009 Jan; 110(1):58-63. PubMed ID: 18847340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
    Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
    Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
    Ehlert A; Schmidt C; Wölfer J; Manthei G; Jacobs AH; Brüning R; Heindel W; Ringelstein EB; Stummer W; Pluta RM; Hesselmann V
    J Neurosurg; 2016 Jan; 124(1):51-8. PubMed ID: 26162034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
    Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
    Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]).
    Hänggi D; Etminan N; Aldrich F; Steiger HJ; Mayer SA; Diringer MN; Hoh BL; Mocco J; Faleck HJ; Macdonald RL;
    Stroke; 2017 Jan; 48(1):145-151. PubMed ID: 27932607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients.
    Cho S; Bales J; Tran TK; Korab G; Khandelwal N; Joffe AM
    Ann Pharmacother; 2016 Sep; 50(9):718-24. PubMed ID: 27273676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
    Carlson AP; Hänggi D; Wong GK; Etminan N; Mayer SA; Aldrich F; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Bleck T; Grubb R; Miller M; Suarez JI; Proskin HM; Macdonald RL;
    Stroke; 2020 Apr; 51(4):1142-1149. PubMed ID: 32138631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
    van den Bergh WM; Mees SM; Rinkel GJ
    Neurosurgery; 2006 Nov; 59(5):E1152; author reply E1152. PubMed ID: 17143226
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
    Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM
    J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
    Hajizadeh Barfejani A; Rabinstein AA; Wijdicks EFM; Clark SL
    J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2155-2158. PubMed ID: 31103551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study.
    Westermaier T; Stetter C; Vince GH; Pham M; Tejon JP; Eriskat J; Kunze E; Matthies C; Ernestus RI; Solymosi L; Roosen K
    Crit Care Med; 2010 May; 38(5):1284-90. PubMed ID: 20228677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
    Sandow N; Diesing D; Sarrafzadeh A; Vajkoczy P; Wolf S
    Neurocrit Care; 2016 Aug; 25(1):29-39. PubMed ID: 26690937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study.
    Soppi V; Kokki H; Koivisto T; Lehtonen M; Helin-Tanninen M; Lehtola S; Rinne J
    Eur J Clin Pharmacol; 2007 Apr; 63(4):355-61. PubMed ID: 17318527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
    Cho WS; Kang HS; Kim JE; Kwon OK; Oh CW; Son YJ; Know BJ; Jung C; Hang MH
    Interv Neuroradiol; 2011 Jun; 17(2):169-78. PubMed ID: 21696654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.
    Peacock SH; James C; Turnbull MT; Cowart JB; Reid JM; Freeman WD
    J Neurosci Nurs; 2019 Oct; 51(5):238-242. PubMed ID: 31469704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
    Samseethong T; Suansanae T; Veerasarn K; Liengudom A; Suthisisang C
    Ann Pharmacother; 2018 Nov; 52(11):1061-1069. PubMed ID: 29783859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics.
    Vázquez-Medina A; Turnbull MT; James CL; Cowart JB; Lesser E; Carter RE; Ross OA; Miller DA; Meschia JF; De Jesús Espinosa A; Weinshilboum R; Freeman WD
    Pharmacogenomics J; 2024 Jun; 24(4):19. PubMed ID: 38890281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion.
    Doukas A; Petridis AK; Barth H; Jansen O; Maslehaty H; Mehdorn HM
    Acta Neurochir Suppl; 2011; 112():93-6. PubMed ID: 21691994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.